Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Shares Outstanding (2017 - 2025)

Aclaris Therapeutics has reported Shares Outstanding over the past 9 years, most recently at $120.5 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $120.5 million for Q4 2025, up 11.73% from a year ago — trailing twelve months through Dec 2025 was $120.5 million (up 11.73% YoY), and the annual figure for FY2025 was $120.5 million, up 11.73%.
  • Shares Outstanding for Q4 2025 was $120.5 million at Aclaris Therapeutics, up from $108.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding for ACRS hit a ceiling of $120.5 million in Q4 2025 and a floor of $8.1 million in Q2 2021.
  • Median Shares Outstanding over the past 5 years was $70.8 million (2023), compared with a mean of $74.6 million.
  • Biggest five-year swings in Shares Outstanding: crashed 81.03% in 2021 and later skyrocketed 723.2% in 2022.
  • Aclaris Therapeutics' Shares Outstanding stood at $61.2 million in 2021, then grew by 8.92% to $66.7 million in 2022, then grew by 6.31% to $70.9 million in 2023, then skyrocketed by 52.13% to $107.9 million in 2024, then increased by 11.73% to $120.5 million in 2025.
  • The last three reported values for Shares Outstanding were $120.5 million (Q4 2025), $108.3 million (Q3 2025), and $108.3 million (Q2 2025) per Business Quant data.